ORIGINAL RESEARCH ARTICLE ORIGINAL RESEARCH ARTICLE BACKGROUND: Clinical trials of bone marrow cell-based therapies after acute myocardial infarction (MI) have produced mostly neutral results. Treatment with specific bone marrow cell-derived secreted proteins may provide an alternative biological approach to improving tissue repair and heart function after MI. We recently performed a bioinformatic secretome analysis in bone marrow cells from patients with acute MI and discovered a poorly characterized secreted protein, EMC10 (endoplasmic reticulum membrane protein complex subunit 10), showing activity in an angiogenic screen.
I
mproved reperfusion strategies and healthcare logistics have shortened ischemic times and enhanced myocardial salvage in most patients with acute myocardial infarction (MI). 1 Despite these achievements, patients with extensive myocardial injury during the acute phase remain at risk of developing heart failure and continue to have increased mortality. [2] [3] [4] MI triggers an inflammatory response that replaces the necrotic area with vascularized granulation tissue and eventually a collagen-rich scar. The heart can undergo deleterious changes in left ventricular (LV) geometry and function during this vulnerable period before scar formation has stabilized the infarct area. 5 Therapeutic modulation of infarct healing may therefore hold promise for preventing postinfarction heart failure. Indeed, targeted therapies that either limit excessive inflammation or promote angiogenesis in the infarct wound attenuate adverse LV remodeling and systolic dysfunction in mice with acute MI. [6] [7] [8] [9] In patients, intracoronary infusion of autologous bone marrow cells (BMCs) during this critical time window has been explored as an adjunctive therapeutic strategy to improve heart function after MI. 10 Transcriptome and proteome analyses indicate that various BMC populations release a broad repertoire of cytokines and growth factors that may enhance tissue repair in a paracrine manner, thus providing a conceptual framework for this approach. [11] [12] [13] Clinical trials investigating the efficacy of BMC therapy after MI have produced mostly neutral results; however, and a recent meta-analysis by the Cochrane Collaboration concluded that there is insufficient evidence for a beneficial effect.
14 Indeed, several issues complicate the therapeutic use of autologous BMCs. 15 The approach is limited by low cell retention rates after intracoronary or intramyocardial delivery 16, 17 and by interindividual variations in cell functionality. 18, 19 Moreover, the therapeutically active cell populations and paracrine factors in heterogeneous BMC preparations remain ill defined. Systemic application of specific BMC-derived secreted proteins may be an alternative biological approach to improving tissue repair and heart function after MI.
We recently performed a bioinformatic secretome analysis in BMCs from patients with acute MI who were enrolled in the BOOST-2 cell therapy trial (Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration 2). 20, 21 From this analysis, we identified a poorly characterized secreted protein, encoded by an open reading frame on chromosome 19 (C19orf63) , that showed biological activity in an angiogenic screen. The same protein had previously been cloned from hematopoietic stem cells and was named HSS1 (hematopoietic signal peptide-containing secreted 1). 22 A splice variant containing a C-terminal transmembrane domain was designated HSM1 (hematopoietic signal peptide-containing membrane domain-containing 1). 22 In a proteomics screen, HSM1 emerged as a component of the endoplasmic reticulum membrane protein complex, which has been implicated in endoplasmic reticulum-mitochondria interactions and endoplasmic reticulum-associated protein assembly and degradation. 23 Although the role of HSM1 (if any) within this protein complex has not been defined, the gene encoding HSS1 and HSM1 is now officially called endoplasmic reticulum membrane protein complex subunit 10 (EMC10). Under baseline conditions, EMC10 is widely expressed in many tissues, including bone marrow and spleen; the highest expression levels have been found in kidneys, prostate gland, and testis. 24 The mouse homolog of EMC10 (Emc10) has been identified as an inhibitor of dendritic development in mice with a schizophrenia-related chromosomal microdeletion. 25 Otherwise, the function of this protein was hitherto unknown. Here, we explored the angiogenic effects and therapeutic potential of Emc10 in a mouse model of reperfused acute MI.
Clinical Perspective
What Is New?
• EMC10 (endoplasmic reticulum membrane protein complex subunit 10) is a previously unknown angiogenic growth factor that we discovered in a bioinformatic secretome analysis in bone marrow cells from patients with acute myocardial infarction.
• EMC10 and its mouse homolog (Emc10) signal via small GTPases, p21-activated kinase, and p38 mitogen-activated protein kinase to promote endothelial cell migration.
• Bone marrow-derived monocytes and macrophages produce Emc10 endogenously to enhance infarct vascularization, tissue repair, and heart function in mice with acute myocardial infarction.
• Subcutaneous treatment with recombinant Emc10 for 1 week after myocardial infarction augments infarct vascularization and repair and leads to a sustained improvement in heart function and survival in heart failure-prone FVB/N mice.
What Are the Clinical Implications?
• Functional annotation of the human bone marrow cell secretome provides an opportunity to identify previously unknown paracrine factors with therapeutic potential.
• This study supports the idea that therapeutic modulation of infarct healing holds promise for preventing postinfarction heart failure. • This study should stimulate further research into the role of EMC10 in other disease states and its therapeutic potential for ischemic tissue repair.
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METHODS
Reagents
Recombinant human and mouse vascular endothelial growth factor A (VEGFA and Vegfa) were purchased from R&D Systems, brefeldin A and SB203580 from Cell Signaling Technology, and ML141 from Merck Millipore.
Antibodies
A polyclonal antibody against a peptide sequence (amino acids 208-221) shared by Emc10-1 (transmembrane isoform) and Emc10-2 (secreted isoform), as well as by EMC10-1 and EMC10-2, was raised in rabbits and purified by reversed-phase high-performance liquid chromatography by Eurogentec. Other antibodies used for immunoblotting and immunostaining are listed in the Methods in the online-only Data Supplement.
Recombinant Emc10
Emc10 (amino acids 1-221, corresponding to the extracellular part of Emc10-1 that is shared by both isoforms) was produced with a C-terminal 6×His-tag in HEK-293 cells (GenScript). Please refer to the Methods in the online-only Data Supplement for details on protein purification and quality control.
Expression of EMC10 in HEK-293 Cells
Expression plasmids (pcDNA/V5-HisA, Thermo Fisher Scientific) encoding EMC10-1, EMC10-1 lacking the N-terminal signal peptide (ΔSP), EMC10-2, or EMC10-2ΔSP were transfected into HEK-293 cells with the X-tremeGENE 9 transfection reagent (Roche 26 that abolishes mRNA and protein expression of both isoforms. 25 The animals had been backcrossed for >10 generations to the C57BL/6J strain 25 and were maintained on that background by heterozygous matings. Wildtype (WT) and KO alleles were detected by polymerase chain reaction (PCR) using a forward primer located in intron 1 (GGATCAGGGAGTGATTTAGTGG) and 2 reverse primers located in intron 1 (CATTCAGGTTTTCATTCACGAG) and the gene trap (CTCAATAAAAGAGCCCACAACC). 25 WT and KO littermates were used in all experiments. Generation of Emc10 bone marrow-chimeric mice is described in the Methods in the online-only Data Supplement. Global mitogen-activated protein kinase (MAPK)-activated protein kinase 2 (Mk2) KO mice (Mapkapk2 tm1Mgl ) have been described. 27 Transgenic mice expressing green fluorescent protein under the control of the murine endothelium-specific receptor tyrosine kinase (Tek; also known as Tie2) promoter (Tg[TIE2GFP]287Sato) were obtained from The Jackson Laboratory.
28
Angiogenesis Assays
Human umbilical vein endothelial cells (HUVECs) and human coronary artery endothelial cells (HCAECs) were purchased from Provitro. Cardiac endothelial cells were isolated from LVs of 7-to 9-day-old Mk2 WT and KO mice as previously described. 29 Cell proliferation was measured by a colorimetric BrdU incorporation immunoassay (Roche); branching morphogenesis was assessed on growth factor-reduced Matrigel (Corning); and cell migration was analyzed after scratch injury (refer to Methods in the online-only Data Supplement for details).
The amount of free globular (G)-actin and filamentous (F)-actin was determined with the G-Actin/F-Actin In Vivo Assay Biochem Kit from Cytoskeleton, Inc. HCAECs were homogenized in F-actin stabilization buffer and then ultracentrifuged (100 000g for 1 hour at 4°C) to separate the G-actin and F-actin pools. The fractions were separated by SDS-PAGE, and actin was quantified by immunoblotting.
HUVECs were transfected with expression plasmids (pcDNA/V5-HisA) encoding EMC10-1, EMC10-1ΔSP, EMC10-2, EMC10-2ΔSP, or VEGFA (1.5 μg/10 5 cells) using the Targefect-HUVEC reagent (Targeting Systems). Transfection efficiency in this system was 44±2% as assessed by cotransfection of an enhanced green fluorescent protein-encoding expression plasmid. HUVECs were transfected with small interfering RNAs (siRNAs) (Thermo Fisher Scientific) against either p21-activated kinase (PAK) 2 or heat shock protein family B (small) member 1 (HSPB1) or with control siRNA (25 pmol/10 5 cells) using the Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific). At 48 hours after transfection, cells were used for functional assays.
RAC1/CDC42 Activity Assay
RAC1/CDC42 activation in HCAECs was measured with an assay (No. 17-441, Merck Millipore) that uses the RAC1/ CDC42 downstream effector PAK1 to isolate the active GTPbound forms of RAC1 and CDC42 from cell lysates. Activated RAC1 and CDC42 were then detected by immunoblotting with specific monoclonal antibodies.
Mouse Surgery and Functional Assessment
All animal procedures were approved by our local authorities (Niedersächsisches Landesamt für Verbraucherschutz und Lebensmittelsicherheit). MI was induced in 8-to 10-weekold male mice by transient left anterior descending coronary artery ligation (see Methods in the online-only Data Supplement for details). To assess postinfarction survival, mice were inspected daily up to 28 days. Autopsies were performed on all dead animals; heart failure was diagnosed by chest fluid accumulation and cardiac rupture by the presence of a blood clot around the heart. 30 LV function was assessed by high-resolution 2-dimensional transthoracic echocardiography and by invasive pressure-volume measurements (see Methods in the online-only Data Supplement for details). Tailcuff blood pressure and heart rate were measured with a BP 2000 Blood Pressure Analysis System (VisiTech). Osmotic minipumps (model 1007D, Alzet; pumping rate, 0.5 μL/h) filled with recombinant Emc10 (10 μg/12 μL) or diluent (PBS) were placed in a subcutaneous interscapular pocket just before coronary reperfusion. EDTA blood samples were drawn from the facial vein. Peripheral blood counts were obtained with a scil Vet ABC Hematology Analyzer (scil animal care company).
Cardiac Tissue Explants
Mice were euthanized 1 day after MI, and the hearts were removed. The infarcted and noninfarcted regions of the LV were dissected into ≈1-mm 3 tissue samples. The samples were cultured for 3 days in endothelial basal medium on growth factor-reduced Matrigel in 48-well plates (1 sample per well) and imaged by phase-contrast or fluorescence microscopy. Endothelial sprouts were stained with a mouse CD31 monoclonal antibody (clone MEC 13.3; 1:100) and a Cy3-labeled polyclonal secondary antibody from Jackson ImmunoResearch (No. 712-165-153; 1:200). Average sprout length was calculated from 8 sprouts per sample.
Tissue Collection
Mice were euthanized at different time points after MI or sham operation, and the hearts were removed. For later isolation of protein and mRNA, the LVs were divided into the infarcted region (anteroapical wall distal to the left anterior descending coronary artery ligation site representing the infarcted area and border zone) and noninfarcted region (basal part of the interventricular septum). Tissues were snap-frozen in liquid N 2 . For histology, basal, midventricular, and apical slices of the LV were embedded in optimum cutting temperature compound (Tissue-Tek) and frozen at −80°C. Histology techniques are described in the Methods in the online-only Data Supplement.
Emc10-Targeted Liquid ChromatographyMass Spectrometry
We established a targeted liquid chromatography-mass spectrometry assay to measure Emc10 in the circulation of mice (see Methods in the online-only Data Supplement for details).
Quantitative Reverse Transcription-PCR
Total RNA was isolated from cells and tissues with the RNeasy RNA isolation kit (Qiagen) followed by reverse transcription into cDNA (SuperScript III reverse transcriptase, Thermo Fisher Scientific). The mRNA concentrations of Emc10-1 and Emc10-2 were measured by quantitative PCR with TaqMan gene expression assays and reagents from Thermo Fisher Scientific.
Cell Isolation
BMCs were flushed from the femurs and tibias. Peripheral blood was drawn from the right ventricle. Splenocyte suspensions were prepared with a gentleMACS dissociator (Miltenyi Biotec). Erythrocytes were depleted by NH 4 Cl lysis.
Inflammatory cells and endothelial cells were isolated by enzymatic digestion from the infarcted region. 21, 29 Gating strategies used for fluorescence-activated cell sorting and flow cytometry are described in the Methods in the online-only Data Supplement. To generate conditioned supernatants, BMCs and splenocytes were cultured in serum-free Iscove's modified Dulbecco's medium. Monocytes were isolated from the enzymatically digested infarcted region with a kit from Miltenyi Biotec (No. 130-100-629) and cultured in the same medium. After 24 hours, conditioned supernatants and cell lysates were collected. Supernatants were concentrated with Amicon Ultra-4 centrifugal filters.
Statistical Analyses
Data are presented as mean±SEM. Visual inspection indicated that data were normally distributed with similar variances in the different groups. With small sample sizes, we did not apply statistical tests for normality or equality of variances. Numbers refer to the number of independent experiments or mice. The 2-independent-sample t test was used to compare 2 groups. For comparisons among >2 groups, 1-way ANOVA was used if there was 1 independent variable and 2-way ANOVA if there were 2 independent variables. The Tukey post hoc test was used to adjust for multiple comparisons. The Dunnett post hoc test was used for multiple comparisons with a single control group. Differences in cumulative survival after MI were illustrated by a Kaplan-Meier curve and analyzed by the log-rank test. A 2-tailed value of P<0.05 indicated statistical significance.
The senior author (K.C.W.) had full access to all the data in the study and takes responsibility for the integrity of the data and the data analysis.
RESULTS
EMC10 Is an Angiogenic Growth Factor
We recently identified 42 poorly characterized, putatively secreted proteins in a bioinformatic secretome analysis in human BMCs ( Figure IA in the online-only Data Supplement). 21 One of these proteins, EMC10-2 (previously known as HSS1), stimulated endothelial cell proliferation and network formation in an angiogenic screen ( Figure IB in the online-only Data Supplement). 21 The UniProt database (http://www.uniprot.org/uniprot/ Q5UCC4) lists EMC10-2 as a secreted protein and its splice variant EMC10-1 (previously known as HSM1) as a single-pass type I membrane protein with its Nterminus protruding into the extracellular space; both isoforms are processed via the classic secretory pathway ( Figure 1A ).
We generated expression plasmids encoding either EMC10-1 or EMC10-2, transfected them into HEK-293 cells, and used immunoblotting to detect EMC10 in the cell lysate and conditioned supernatant ( Figure 1B ). As a membrane protein, EMC10-1 was retained in the cell lysate. In contrast, EMC10-2 was detectable in the cell lysate and released into the supernatant. Secretion of EMC10-2 was not associated with a release of GAPDH, thus excluding cell lysis ( Figure 1B) . Release of EMC10-2 was prevented by brefeldin A, an inhibitor of the classic secretory pathway, 31 or by deletion of the signal peptide, thereby confirming EMC10-2 as a classically secreted protein. EMC10-2 is heavily glycosylated as it moves along the secretory pathway in HEK-293 cells. 22 Consistent with that previous report, EMC10-2 generated several bands on the immunoblot ( Figure 1B) .
Expression of either EMC10-1 or EMC10-2 in HUVECs enhanced cell proliferation ( Figure 1C ) and gap closure in a confluent endothelial cell monolayer scratch assay ( Figure 1D) , showing that both isoforms can promote angiogenic effects. EMC10-1 or EMC10-2 lacking the signal peptides were inactive in these assays, indicating that both isoforms need to enter the secretory pathway to promote their biological effects. Addition of the polyclonal EMC10 antibody to the culture medium abrogated the angiogenic effects of both isoforms in the scratch assay ( Figure 1E ).
We next assessed the angiogenic potential of recombinant Emc10 in HCAECs. Emc10 stimulated endothelial cell proliferation ( Figure 1F ) and network formation ( Figure 1G ), thus confirming the results from the angiogenic screen. Emc10 also promoted gap closure in a confluent endothelial monolayer scratch assay ( Figure 1H ). The angiogenic effects of Emc10 were concentration-dependent. Restoring endothelial monolayer integrity after scratching involves cell proliferation and migration. 32 We therefore used time-lapse video microscopy and automated nuclear tracking to specifically explore whether Emc10 influences endothelial cell migration. Although Emc10 did not enhance single-cell velocity ( Figure 1I ), it stimulated more directed endothelial cell migration into the cell-free space and consequently engendered more efficient gap closure ( Figure 1I ).
Emc10 Promotes Endothelial Cell Migration via Small GTPases, PAK2, and p38 MAPK
We next explored the signaling pathways involved in Emc10-induced cell migration. Recombinant Emc10 rapidly (within 0.5 minutes) activated the small GTPases CDC42 and RAC1 in HCAECs as assessed by measurement of GTP-bound CDC42 and RAC1 levels (Figure 2A) . Downstream of the small GTPases, Emc10 increased the phosphorylation (P) of PAK as shown by immunoblotting with an antibody detecting P-PAK1 (S199/204) and P-PAK2 (S192/197; Figure 2B ). The P-PAK signal was abolished after transfection with a PAK2-specific siRNA (Figure 2B) , thereby confirming PAK2 as the main isoform expressed in endothelial cells. 33 On binding to activated small GTPases, PAKs are activated by autophosphorylation of serine residues, including S192/197 in PAK2. 34 Consistent with PAK2 activation, P-PAK2 (S192/197) was localized in filopodia extending into the cell-free space in scratched endothelial cell monolayers stimulated with Emc10 ( Figure 2C ). Emc10 also increased the phosphorylation of p38 MAPK and its substrate, MK2 Figure 2D ). This was accompanied by increased phosphorylation of the MK2 substrate and actin capping protein HSPB1 on S82 as shown by immunoblotting ( Figure 2D ) and immunofluorescent staining ( Figure 2E ). Further downstream, Emc10 promoted actin polymerization as shown by more pronounced phalloidin staining of F-actin ( Figure 2F ) and an increased F-actin/G-actin ratio ( Figure 2G ).
Inhibiting p38 MAPK with SB203580 prevented Emc10-induced actin polymerization ( Figure 2F and 2G). Emc10-induced phosphorylation of PAK2 and p38 MAPK was attenuated by ML141, a CDC42 inhibitor, 35 thus placing PAK2 and p38 MAPK downstream of this small GTPase ( Figure 2H ). Confirming HSPB1 as a target of the p38 MAPK-MK2 pathway, SB203580 (FigFigure 1 Continued. encoding EMC10-1, EMC10-2, or EMC10-2 lacking the N-terminal SP (ΔSP). Cells were treated with brefeldin A (BA; 10 μmol/L) as indicated. L indicates cell lysates; and SN, conditioned supernatants. C, BrdU incorporation over 16 hours in human umbilical vein endothelial cells (HUVECs) expressing EMC10-1, EMC10-1ΔSP, EMC10-2, EMC10-2ΔSP, or vascular endothelial growth factor A (VEGFA); an empty expression plasmid served as control (n=5-6). D, Recovery 16 hours after scratch injury of HUVEC monolayers expressing EMC10-1, EMC10-1ΔSP, EMC10-2, EMC10-2ΔSP, or VEGFA; an empty expression plasmid served as control (n=5-7). E, Recovery 16 hours after scratch injury of HUVEC monolayers expressing EMC10-1, EMC10-2, or VEGFA in the presence or absence of the polyclonal EMC10 antibody (Ab) or a control Ab directed against myeloid-derived growth factor 21 ; an empty expression plasmid served as control (n=4). *P<0.05, ***P<0.001 vs. no Ab in each plasmid group (1-way ANOVA with Dunnett post hoc test). F, BrdU incorporation over 16 hours in human coronary artery endothelial cells (HCAECs) cultured in the absence (control) or presence of VEGFA (50 ng/mL) or Emc10 (at indicated concentrations; n=4-5). G, Fluorescent microscopy images and summary data (n=3) of HCAECs cultured for 16 hours in the absence (control) or presence of Emc10 (100 ng/mL) or VEGFA (50 ng/mL) and stained with the fluorescent dye BCECF-AM (scale bar, 500 μm). H, Recovery 16 hours after scratch injury of HCAEC monolayers cultured in the absence (control) or presence of VEGFA (50 ng/mL) or Emc10 (at indicated concentrations). Example phase-contrast images (initial scratch indicated with dashed line) and summary data (n=6) are shown (scale bar, 500 μm). I, Average single-cell migratory velocity and directionality ratio after scratch injury of HCAEC monolayers cultured in the absence (control) or presence of VEGFA (50 ng/mL), Emc10 (100 ng/mL), or endothelial cell growth medium (EGM; n=8-10). Example time-lapse video microscopy images of scratched HCAEC monolayers (left) and individual cell tracks assembled around the same virtual starting point (right) are shown (scale bars, 100 μm). For C, D, F, G, H, and I, *P<0 .05, **P<0.01, ***P<0.001 vs. control (1-way ANOVA with Dunnett post hoc test).
ure 2I) and siRNA-mediated downregulation of MK2 ( Figure 2J ) reduced Emc10-induced HSPB1 phosphorylation. Furthermore, ML141 and SB203580 ( Figure 2K ), as well as siRNA-mediated downregulation of PAK2 or HSPB1 ( Figure 2L ), suppressed the effects of Emc10 on gap closure after scratch injury, thereby establishing the importance of these signaling pathways for Emc10-induced cell migration. We next assessed the effects of Emc10 on endothelial cell behavior in the context of acute MI induced by transient coronary artery ligation in mice. This model simulates the situation in patients with acute MI receiving reperfusion therapy and was used throughout this study. At 24 hours after reperfusion, tissue samples from the infarcted and noninfarcted regions of the LV were explanted and cultured on Matrigel. Emc10 stimulated endothelial cell outgrowth from the infarcted region in an SB203580-sensitive manner, whereas no cellular outgrowth from the noninfarcted region was observed (Figure 3A) . Emc10 did not enhance cellular outgrowth from infarcted tissue samples obtained from Mk2 KO mice ( Figure 3B ). Emc10 also failed to promote gap closure after scratch injury in cardiac endothelial cell monolayers isolated from Mk2 KO mice ( Figure 3C ), thus confirming the importance of the p38 MAPK-MK2 pathway for Emc10-induced cardiac endothelial cell migration.
Emc10 Is Expressed by Monocytes and Macrophages After MI
We next explored whether Emc10 is present in the heart or circulation of WT mice after MI. As shown by immunoblotting with our antibody that recognizes both isoforms, Emc10 expression was increased in the infarcted A and B, Myocardial infarction was induced in wild-type (WT), Tie2-green fluorescent protein (GFP)-transgenic, and Mk2 knockout (KO) mice. After 24 hours, tissue samples from the infarcted and noninfarcted regions of the left ventricle were removed and cultured for 3 days in the absence (control) or presence of Emc10 (100 ng/mL), vascular endothelial growth factor a (Vegfa; 50 ng/mL), or SB203580 (SB; 10 μmol/L). A, Example tissue samples imaged by phase contrast (PC) or fluorescence microscopy with CD31 immunostaining or GFP fluorescence (scale bar, 500 μm). Bar graph depicts average sprout length in infarcted tissue samples from WT mice (n=4-5). B, Average sprout length in infarcted tissue samples from WT and Mk2 KO mice (n=6-7). C, Recovery 16 hours after scratch injury of cardiac endothelial cell monolayers established from WT or Mk2 KO mice and cultured in the absence (control) or presence of Emc10 (100 ng/mL), Vegfa (50 ng/mL), or endothelial cell growth medium (EGM; n=8). *P<0.05, **P<0.01, ***P<0.001 vs. control. #P<0.05, ##P<0.01 (1-way ANOVA with Tukey post hoc test in A; 2-way ANOVA with Tukey post hoc test in B and C).
region of the LV compared with sham-operated control mice ( Figure 4A ). Emc10 expression peaked 3 days after MI and declined thereafter. Emc10 was not significantly induced in the noninfarcted region ( Figure 4A ). As shown by targeted liquid chromatography-mass spectrometry, the circulating (plasma) levels of Emc10 were also increased 3 days after MI ( Figure 4B ). EMC10 was also expressed in LV tissue samples from patients who had died of acute MI; expression levels were higher than in patients who had died of noncardiac causes ( Figure 4C ).
Confocal immunofluorescence microscopy showed that Emc10 was expressed by small, roundish cells often found near endothelial cells in the infarcted region in mice ( Figure 4D ). Of the Emc10-expressing cells, 85±2% coexpressed the macrophage marker F4/80 (data from 6 mice; example image is shown in Figure 4D) . We detected no immunofluorescence signal in the infarcted region of Emc10 KO mice (described below), thus validating the specificity of the antibody (Figure 4D) . Quantitative reverse transcription-PCR with isoform-specific primer pairs showed that both Emc10 isoforms were upregulated in the infarcted region of WT mice, reaching maximum expression 3 days after MI ( Figure 4E ). Both isoforms were expressed predominantly by Ly6C high monocytes and Ly6C low monocytes or macrophages isolated by fluorescence-activated cell sorting from the infarcted region ( Figure 4F ). Emc10 expression was much less pronounced in neutrophils, T cells, B cells, and endothelial cells ( Figure 4F) . Similarly, both isoforms were expressed predominantly by monocytes and macrophages from bone marrow, spleen, and peripheral blood 3 days after MI ( Figure 4F ). Monocytes and macrophages from bone marrow, spleen, and peripheral blood also expressed both Emc10 isoforms under sham-operated conditions ( Figure II in the online- only Data Supplement). To explore whether Emc10 is secreted from inflammatory cells, we isolated monocytes from the infarcted region, BMCs, and splenocytes 3 days after MI and cultured the cells for 24 hours. As shown by immunoblotting, all 3 cell types secreted Emc10 into the supernatant ( Figure 4G ).
Inflammatory Cell-Derived Emc10 Promotes Angiogenesis in the Infarcted Heart
We subjected Emc10 WT and KO mice to transient coronary artery ligation to explore the function of endogenous Emc10 after MI. KO mice did not express either of the 2 Emc10 isoforms in the LV after MI or sham operation ( Figure IIIA and IIIB in the online-only Data Supplement). Furthermore, KO mice showed no obvious cardiovascular phenotype under baseline conditions: body mass, select organ masses, LV mass, LV end-diastolic and end-systolic dimensions, LV systolic function (fractional area change), heart rate, tail-cuff blood pressure (Table I in the online-only Data Supplement), and peripheral blood count (Table II in the online-only Data  Supplement) were not significantly different between WT and KO mice.
Area at risk and infarct size were not significantly different between WT and KO mice 24 hours after MI ( Figure IIIC in the online-only Data Supplement). As shown by flow cytometry, accumulation of neutrophils, Ly6C high monocytes, Ly6C low monocytes or macrophages, T cells, and B cells in the infarcted area at 2 and 6 days after MI were comparable between WT and KO mice ( Figure IIID in the online-only Data Supplement). Capillary density increased in the infarct border zone 6 and 28 days after MI in WT mice, but this angiogenic response was significantly blunted in KO mice ( Figure 5A ). Capillary density in the noninfarcted region of the LV was comparable between WT and KO mice ( Figure IIIE in the online-only Data Supplement). Moreover, capillary density in the LV was not significantly different between WT and KO mice after sham surgery ( Figure 5A ), thus indicating that genetic ablation of Emc10 specifically impairs angiogenesis during ischemic tissue repair. Increased angiogenesis in WT mice was preceded by increased expression and S86 phosphorylation of Hspb1 in the border zone 2 days after MI ( Figure 5B ). Hspb1 expression increased to a similar extent in KO mice, but phosphorylation of Hspb1 was significantly reduced ( Figure 5B ). KO mice developed larger infarct scars ( Figure 5C ) and more pronounced LV remodeling and systolic dysfunction on echocardiography ( Figure 5D and 5E) compared with WT mice. LV pressure-volume measurements reinforced these findings and showed that postinfarction systolic and diastolic dysfunction was more severe in KO than in WT mice (Figure IIIF and Table III in the  online-only Data Supplement) .
We generated bone marrow-chimeric mice to specifically address the importance of inflammatory cellderived Emc10 for ischemic tissue repair. No Emc10 was detectable in the infarcted region of the LV after Emc10 KO BMCs were transplanted into KO mice (Figure 5F ). Transplanting WT BMCs into KO mice substantially increased Emc10 expression ( Figure 5F ). On the other hand, Emc10 expression in the infarcted region was significantly lower in WT mice transplanted with KO BMCs than in WT mice transplanted with WT BMCs (Figure 5F ), thus confirming bone marrow-derived inflammatory cells as a major source of Emc10 after MI. Quantitative reverse transcription-PCR with isoformspecific primer pairs supported this conclusion and indicated that bone marrow-derived inflammatory cells express both isoforms in the infarcted region ( Figure IIIG in the online-only Data Supplement).
Transplanting WT BMCs into KO mice enhanced angiogenesis in the infarct border zone ( Figure 5G ), reduced final scar size ( Figure 5H ), and attenuated LV remodeling and systolic dysfunction ( Figure 5I and 5J) . Conversely, transplanting KO BMCs into WT mice impaired the angiogenic response, increased scar size, and worsened LV remodeling and systolic dysfunction ( Figure 5G-5J) , indicating that Emc10 produced by bone marrow-derived inflammatory cells is sufficient and required for angiogenesis and functional adaptation after MI.
Emc10 Protein Therapy
We used FVB/N mice, a strain that is prone to developing heart failure after ischemic injury, 30 to assess the therapeutic potential of Emc10 after MI. Because the angiogenic response occurs mainly during the first week after MI, we treated the animals with recombinant Emc10 for 7 days after transient coronary artery ligation using subcutaneously implanted osmotic minipumps to ensure continuous protein delivery ( Figure 6A ). Emc10 protein therapy enhanced S86 phosphorylation of Hspb1 ( Figure 6B ) and capillary density in the infarct border zone 2 and 6 days after reperfusion ( Figure 6C ). The angiogenic effects of Emc10 were maintained at 28 days ( Figure 6C ) and resulted in higher numbers of perfused capillaries (Figure 6D) . Capillary density in the noninfarcted region of the LV was not affected by Emc10 ( Figure IVA in the online-only Data Supplement). Emc10-treated mice developed smaller infarct scars ( Figure 6E ) and less pronounced LV remodeling and systolic dysfunction ( Figure 6F and 6G) . The effects of Emc10 on systolic function were evident at 6 days, were maintained at 28 days, and were associated with significantly reduced mortality ( Figure 6H ). Serous fluid accumulation in the chest cavity, which indicates heart failure, was found in all dead animals; no lethal cardiac ruptures were observed. LV pressure-volume measurements confirmed the therapeutic effects of Emc10 on systolic function (Figure IVB and Table IV in the online-only Data Supplement).
DISCUSSION
After ischemic injury and during the development of heart failure, the heart responds to numerous secreted proteins that are produced and function locally within the myocardium. Although secreted proteins, includ- .001 (2-independent-sample t tests). F through J, Bone marrow cells from WT or KO mice were transplanted into (→) lethally irradiated KO or WT recipients. After bone marrow reconstitution, MI was induced. F, Example immunoblots and summary data showing Emc10 (both isoforms) and Gapdh expression in the infarcted region of the LV 3 days after MI (4-6 mice per group). *P<0.05, **P<0.01 (2-independent-sample t tests). G, Fluorescein-labeled IB4 + capillary density in the infarct border zone 28 days after MI (5-7 mice per group). **P<0.01 (2-independent-sample t tests). H, Scar size 28 days after MI (7-11 mice per group). **P<0.01 (2-independent-sample t tests). I, LVEDA and LVESA 28 days after MI (7-11 mice per group). LVESA, P<0.05, WT→KO vs. KO→KO and KO→WT vs. WT→WT at 28 days (2-independent-sample t tests). J, FAC 28 days after MI; data are from the same animals as in I. Scatterplot shows values from individual mice. Horizontal bars are means. **P<0.01 (2-independent-sample t tests).
ing cytokines, growth factors, and extracellular matrix proteins, are increasingly recognized as being critically involved in tissue repair and remodeling after MI, 36 we probably lack a thorough understanding of most secreted proteins acting on the heart. 37 Here, we identified EMC10 as a previously unknown angiogenic growth factor promoting tissue repair after MI. EMC10 is evolutionarily conserved and widely present in vertebrate species, including amphibians and fishes. 22 Human EMC10 and mouse Emc10 share a high degree of sequence homology, with 92% fully conserved or strongly similar amino acid residues for both the transmembrane (EMC10-1) and secreted (EMC10-2) isoforms. Except for the signal peptide that is shared by both isoforms and the membrane-spanning domain that is unique to EMC10-1, EMC10 contains no known domains or motifs and has no homology with other proteins. 22 On expression in endothelial cells, only full-length EMC10-1 and EMC10-2 (including the signal peptides) promoted angiogenic effects, showing that both isoforms must enter the secretory pathway to be biologically active. Addition of the polyclonal EMC10 antibody to the culture medium abrogated the angiogenic effects of both isoforms, consistent with the idea that EMC10-1 and EMC10-2 act on adjacent cells in a juxtacrine and paracrine manner, respectively (as predicted by UniProt [http://www.uniprot.org/uniprot/Q5UCC4]).
Recombinant Emc10 stimulated proliferation, network formation, and more directed migration of cultured endothelial cells. Emc10 rapidly activated the small GTPases CDC42 and RAC1, suggesting that it may signal through a still-unknown receptor. Small GTPases are known to enhance directed cell migration by promoting the formation of filopodia and lamellipodia at the leading edge of the cell. 38 Downstream of the small GTPases, cytoskeletal reorganization and cell motility are orchestrated by multiple signaling pathways, including PAK and p38 MAPK, with its kinase target MK2. [39] [40] [41] Emc10 activated both signaling cascades via small GTPases to promote endothelial cell migration. Further downstream, Emc10 activation of the p38 MAPK-MK2 pathway led to the phosphorylation of the MK2 substrate HSPB1 and actin polymerization. Phosphorylation of HSPB1 leads to its dissociation from actin and consequently enables actin polymerization and cell migration. [41] [42] [43] [44] Consistently, Emc10 depended on HSPB1 to promote endothelial cell migration. In an ex vivo setup, Emc10 stimulated endothelial cell outgrowth from infarcted tissue samples via p38 MAPK and MK2, thus confirming the importance of these signaling events in the context of acute MI. Using a model of reperfused acute MI in Emc10 KO mice and in FVB/N mice treated with recombinant Emc10, we established that Emc10 is required and sufficient to promote Hspb1 phosphorylation and capillarization of the infarct border zone.
Of note, EMC10 was previously reported to inhibit endothelial cell network formation at concentrations that were 2 orders of magnitude higher than in our study. 45 Lower concentrations were not examined in that previous report, and the in vivo relevance of such extreme concentrations remains unknown.
We identified Ly6C high monocytes and Ly6C low monocytes or macrophages as the main Emc10-producing cells in the infarcted murine heart. Both isoforms showed similar expression levels, as indicated by isoform-specific quantitative reverse transcription-PCR. Other inflammatory cell types and endothelial cells only weakly expressed Emc10. Infarct healing involves the biphasic accumulation of Ly6C high monocytes and Ly6C low monocytes or macrophages that exert distinct and overlapping functions. 46 The bone marrow and spleen continuously supply Ly6C high monocytes via the bloodstream to satisfy the high demand for these cells at the site of inflammation. 47, 48 Recruited Ly6C high monocytes give rise to Ly6C low macrophages that proliferate locally in the infarcted heart. 49 We observed that Ly6C high monocytes in the bone marrow, spleen, and peripheral blood also expressed Emc10 after MI or sham operation. We therefore propose that Emc10-expressing bone marrow-and spleen-derived Ly6C high monocytes are recruited to the infarcted myocardium, continue to express Emc10 as Ly6C low macrophages, and locally produce Emc10 to promote angiogenesis. In support of this model, we found that monocytes from the infarcted region, BMCs, and splenocytes isolated after MI secrete Emc10 in vitro. Notably, the circulating (plasma) levels of Emc10 were also increased after MI, suggesting that Emc10 may also act on target cells via the bloodstream. Our observations in bone marrow-chimeric mice underscore the importance of inflammatory cell-derived Emc10 for microvascularization and preservation of LV systolic function after MI. A similar paradigm may be operative in humans because we identified EMC10 in BMCs from patients with acute MI 21 and found that EMC10 was expressed in the infarcted human heart and that human endothelial cells were responsive to EMC10.
Our study provides proof of principle that treatment with recombinant Emc10 can enhance endogenous Emc10 effects after MI. These findings support the idea that infarct healing affords a time window of therapeutic opportunity wherein transient interventions can have lasting impact on cardiac function. 36 Recombinant proteins can be produced on a large scale with well-standardized protocols; they can be used off the shelf; and they have the potential for noninvasive application, 50 as exemplified here with Emc10. Our study should therefore stimulate further research into the therapeutic potential of Emc10 for ischemic tissue repair.
